Dolly A. Vance
2018
In 2018, Dolly A. Vance earned a total compensation of $1.8M as Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary at Rigel Pharmaceuticals, a 57% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $401,402 |
|---|---|
| Option Awards | $863,124 |
| Salary | $504,508 |
| Other | $1,794 |
| Total | $1,770,828 |
Vance received $863.1K in option awards, accounting for 49% of the total pay in 2018.
Vance also received $401.4K in non-equity incentive plan, $504.5K in salary and $1.8K in other compensation.
Rankings
In 2018, Dolly A. Vance's compensation ranked 6,341st out of 14,244 executives tracked by ExecPay. In other words, Vance earned more than 55.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,341 out of 14,244 | 56th |
Division Manufacturing | 2,426 out of 5,765 | 58th |
Major group Chemicals And Allied Products | 903 out of 2,128 | 58th |
Industry group Drugs | 758 out of 1,817 | 58th |
Industry Pharmaceutical Preparations | 588 out of 1,391 | 58th |
Source: SEC filing on April 9, 2019.
Vance's colleagues
We found five more compensation records of executives who worked with Dolly A. Vance at Rigel Pharmaceuticals in 2018.
2018
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2018
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
2018
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
2018
Esteban Masuda
Rigel Pharmaceuticals
Executive Vice President, Research
2018
Dean Schorno
Rigel Pharmaceuticals